SCHEMBL20099429

SCHEMBL20099429

N#Cc1c(-c2ccccc2)nc(SCc2ccc(CSc3nc(-c4ccccc4)c(C#N)c(=O)[nH]3)cc2)[nH]c1=O

nearest known ligand 0.95

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACMSD Q8TDX5 4/20 0.95
POLB P06746 7/20 0.89
MEN1 O00255 7/20 0.89
KMT2A Q03164 7/20 0.89
TNF P01375 2/20 0.89
NOD2 Q9HC29 2/20 0.89
NOD1 Q9Y239 2/20 0.89
PLA2G1B P04054 1/20 0.89
ATG4B Q9Y4P1 1/20 0.89
ALDH1A1 P00352 2/20 0.75
HPGD P15428 2/20 0.75
CXCR2 P25025 2/20 0.73
BRD4 O60885 1/20 0.73
HSD11B1 P28845 1/20 0.73
PPARG P37231 1/20 0.68
RXFP1 Q9HBX9 1/20 0.68
NCOR2 Q9Y618 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16775370 0.97 ACMSD (0.91) ACMSDPOLBMEN1KMT2ATNF
SCHEMBL16775286 0.95 ACMSD (0.95) ACMSDPOLBMEN1KMT2ATNF
SCHEMBL16775308 0.92 ACMSD (0.81) ACMSDPOLBMEN1KMT2ATNF
SCHEMBL17550092 0.92 ACMSD (1.00) ACMSDPOLBMEN1KMT2ATNF
SCHEMBL16775289 0.92 ACMSD (0.84) ACMSDPOLBMEN1KMT2ATNF
SCHEMBL16772627 0.91 ACMSD (0.83) ACMSDPOLBMEN1KMT2ATNF
SCHEMBL16775278 0.89 ACMSD (0.84) ACMSDPOLBMEN1KMT2ATNF
SCHEMBL16772524 0.89 ACMSD (0.84) ACMSDPOLBMEN1KMT2ATNF
SCHEMBL20099425 0.89 ACMSD (0.76) ACMSDPOLBMEN1KMT2ATNF
SCHEMBL20468620 0.88 MEN1 (0.89) ACMSDPOLBMEN1KMT2ATNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180222880-A1 SecA INHIBITORS AND METHODS OF MAKING AND USING THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-08-09 US disclosed
US-9957247-B2 SecA inhibitors and methods of making and using thereof GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2018-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180222880-A1 SecA INHIBITORS AND METHODS OF MAKING AND USING THEREOF SEC61B, SEC61A1, SEC23A ACMSD 3285/4885POLB 2638/4885MEN1 2848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.